Combining conventional therapy with immunotherapy: A risky business?

A Coosemans; A Vankerckhoven; T Baert; L Boon; H Ruts; M Riva; S Blagden; M Delforge; N Concin; M R Mirza; J A Ledermann; A du Bois; I Vergote

doi:10.1016/j.ejca.2019.02.014

Combining conventional therapy with immunotherapy: A risky business?

A Coosemans, A Vankerckhoven, T Baert, L Boon, H Ruts, M Riva, S Blagden, M Delforge, N Concin, M R Mirza, J A Ledermann, A du Bois, I Vergote

Afdeling for Kræftbehandling CKO

27 Citationer (Scopus)

Abstract

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

Originalsprog	Engelsk
Tidsskrift	European journal of cancer (Oxford, England : 1990)
Vol/bind	113
Sider (fra-til)	41-44
Antal sider	4
ISSN	0959-8049
DOI	https://doi.org/10.1016/j.ejca.2019.02.014
Status	Udgivet - maj 2019

Adgang til dokumentet

10.1016/j.ejca.2019.02.014

Citationsformater

@article{de99beb18508446585d195f415d783b3,

title = "Combining conventional therapy with immunotherapy: A risky business?",

abstract = "Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.",

author = "A Coosemans and A Vankerckhoven and T Baert and L Boon and H Ruts and M Riva and S Blagden and M Delforge and N Concin and Mirza, {M R} and Ledermann, {J A} and {du Bois}, A and I Vergote",

year = "2019",

month = may,

doi = "10.1016/j.ejca.2019.02.014",

language = "English",

volume = "113",

pages = "41--44",

journal = "European journal of cancer (Oxford, England : 1990)",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Combining conventional therapy with immunotherapy

T2 - A risky business?

AU - Coosemans, A

AU - Vankerckhoven, A

AU - Baert, T

AU - Boon, L

AU - Ruts, H

AU - Riva, M

AU - Blagden, S

AU - Delforge, M

AU - Concin, N

AU - Mirza, M R

AU - Ledermann, J A

AU - du Bois, A

AU - Vergote, I

PY - 2019/5

Y1 - 2019/5

N2 - Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

AB - Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

U2 - 10.1016/j.ejca.2019.02.014

DO - 10.1016/j.ejca.2019.02.014

M3 - Journal article

C2 - 30965214

SN - 0959-8049

VL - 113

SP - 41

EP - 44

JO - European journal of cancer (Oxford, England : 1990)

JF - European journal of cancer (Oxford, England : 1990)

ER -

Combining conventional therapy with immunotherapy: A risky business?

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater